What is Citigroup's price target for BPMC?

Citigroup's latest stated price target for Blueprint Medicines Corporation (BPMC) is $41, from its action on Jun 10, 2022.

What is Citigroup's rating on BPMC?

Citigroup rates BPMC Sell, a bearish rating, as of Jun 10, 2022.

When did Citigroup last change its view on BPMC?

On Jun 10, 2022, Citigroup downgrades to Sell from Neutral, price target $68 to $41.

Analyst firms · Citigroup · BPMC

Citigroup BPMC price target and rating history

Blueprint Medicines Corporation (BPMC) · Health Care

Citigroup rates Blueprint Medicines Corporation (BPMC) Sell with a $41 price target, as of its latest action on Jun 10, 2022. It has published 3 rating actions on BPMC since March 2022, including 0 upgrades and 1 downgrade.

Current rating: Sell
Price target: $41
Median target, all firms: Too few
Actions on BPMC: 3

Citigroup price target on BPMC

Citigroup price target on BPMC, each point a stated target, March 2022 to June 2022.

Every Citigroup rating on BPMC

Jun 10, 2022
DowngradeCitigroup downgrades to Sell from Neutral, price target $68 to $41
Mar 1, 2022
InitiateCitigroup starts coverage at Neutral, price target $71
Mar 1, 2022
InitiateCitigroup starts coverage at Neutral

Questions about Citigroup and BPMC

What is Citigroup's price target for BPMC?: Citigroup's latest stated price target for Blueprint Medicines Corporation (BPMC) is $41, from its action on Jun 10, 2022.
What is Citigroup's rating on BPMC?: Citigroup rates BPMC Sell, a bearish rating, as of Jun 10, 2022.
When did Citigroup last change its view on BPMC?: On Jun 10, 2022, Citigroup downgrades to Sell from Neutral, price target $68 to $41.

More BPMC rating histories

All Citigroup ratings BPMC news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.